Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Extended Hours at All Silverman Chiropractic and Rehabilitation Locations


News Image

Since reducing hours, the rehabilitation centers are now open on Mondays, Wednesdays and Fridays at 8 am till 7 pm, Tuesdays at 8 am till 1 pm, and closed on Saturdays.

Silverman Chiropractic and Rehabilitation has now been able to extend its hours once again. During the onset of COVID-19, Mark A Silverman DC has had to minimize the hours to all Silverman Chiropractic and Rehabilitation locations to ensure the safety of staff and patients. Before COVID-19, the hours at each location were Mondays through Fridays from 8 am till 7 pm and Saturday’s at 8 am till 1 pm. Since reducing hours, the rehabilitation centers are now open on Mondays, Wednesdays and Fridays at 8 am till 7 pm, Tuesdays at 8 am till 1 pm, and closed on Saturdays.

Silverman Chiropractic and Rehabilitation offers services include Bilingual Services, Free Transportation, Full Rehabilitation Program, Comprehensive Wellness Programs, specializing in Car Accidents and Slip and Fall, Pain Management, and Physical Therapy. When a patient goes in for the first time, they are first evaluated to see how serious their injuries are. They then undergo an x-ray. After the x-ray is when they get spinal adjustments, therapies, and exercises to ensure they recover.

Mark A Silverman DC has locations all over south Florida to ensure each person in the region can have access to chiropractic care. Their locations are located in Miami, 946 SW 82nd Ave, Miami, FL 33144; Hialeah, 709 E 9th St, Hialeah, FL 33010 and Homestead, 46 N Homestead Blvd, Homestead, FL 33030. No matter where you are located, you will be able to find a Mark A Silverman DC office near you.

Mark A Silverman DC’s staff and doctors are professionals with attention to detail. They are attentive to every patient’s needs and make the process stress free. At Mark A Silverman DC office, all questions are answered and patients are kept up to date with information about their results. Not only are they professional but they treat all the patients like family.

###

With over 35 years of chiropractic care excellence, Silverman chiropractic works with the best medical specialist who will provide all patients with personalized post-accident care. On top of our world-class treatments, Mark A Silverman DC chiropractic care knows how important it is that each patient secures competent medical/legal assistance.


  • Extended hours at all Silverman Chiropractic and Rehabilitation locations
  • Services provided by Mark A Silverman DC
  • Locations in South Florida
  • Best Chiropractic in South Florida

Laura Torres

06/22/2020                                            

(786)566-2064                

Laura@livemediadigital.com

Share article on social media or email:

Mount St. Mary’s University Receives $433,784 NIH Grant for Student Research


Dr. Lombardi

“I think the grant’s success demonstrates the Mount’s commitment to undergraduate research.” – Assistant Professor of Chemistry Patrick Lombardi, Ph.D.

Mount St. Mary’s University received a National Institutes of Health (NIH) Academic Research Enhancement Award, also known as an AREA Grant or an R15, for $433,784 which provides increased summer research opportunities for students, travel to scientific conferences to present their work and learn from others, and access to experimental approaches with state-of-the art laboratory equipment.

“I think the grant’s success demonstrates the Mount’s commitment to undergraduate research,” said Assistant Professor of Chemistry Patrick Lombardi, Ph.D., who serves as the principal investigator. Lombardi’s successful grant proposal, to better understand how the cell’s DNA repair machinery is recruited to sites of DNA damage, included important preliminary data collected from a research group of Mount students.

The Mount’s School of Natural Sciences and Mathematics invested in student success by providing paid research positions for 10 weeks over the summer. As a result of these summer research internships, students’ key findings were included in the NIH grant application.

“Over the last three years, 15 students have worked on this project in our laboratory. Six of these students were Summer Research Internship Award (SRIA) winners,” Lombardi said. “The ability for students to work over the summer, without their usual responsibilities of the academic year, was essential for our group to generate the materials and collect the data necessary for this grant application.”

After receiving good news of the award from Grants Manager Kathy Criasia, Lombardi immediately shared it with his students. “I wanted the students to know they’re making exciting discoveries about an important biological question. I hope they feel a sense of personal accomplishment in the application’s success,” he said. These discoveries can one day lead to effectively diagnosing and responding to diseases that arise from malfunctions in DNA damage repair, Lombardi explained.

Funds from the NIH grant will support six undergraduate researchers working full time in the laboratory for nine-week periods during each of the next three summers and fund equipment use costs at collaborators’ laboratories at Johns Hopkins University. Funds will also pay for reagents necessary to perform the proposed experiments and purchase additional cell growth and protein purification equipment to increase research capacity. The grant will also allow more students to participate in the project and to travel to scientific conferences to present their research. The proposed experiments will be conducted over a three-year funding period from September 15, 2020, to August 31, 2023.

“In my three years at the Mount, I’ve noticed the tremendous positive effect that working in the laboratory over the summer has on our undergraduate researchers,” he said. “By immersing themselves in the laboratory, students are able to master the experimental techniques that are necessary for their projects and become independent researchers. Given their proficiency in the laboratory, these students are then able to continue with their research during the academic year and can accumulate a significant body of work during their undergraduate careers. The laboratory skills and records of accomplishment garnered by these students make them strong candidates for external fellowships that enhance their scientific training even further.”

Lombardi, who received his Bachelor of Science degree in chemistry from Yale University and earned his doctoral degree in chemistry from the University of Pennsylvania, is an ambassador for student research.

In 2012, he was a postdoctoral fellow researching ubiquitin in the laboratory of prominent researcher Cynthia Wolberger at Johns Hopkins University. Lombardi was part of a cohort who showed that in response to a certain type of unwanted DNA modification known as alkylation damage, chains of the protein ubiquitin are assembled in proximity to damage sites to recruit the cell’s DNA repair machinery.

The findings of this discovery were published in 2017 in Nature, a world-renowned scientific journal featuring peer-reviewed research in science, technology and the natural sciences. He is also the recipient of a National Cancer Center Postdoctoral Fellowship Award and an American Cancer Society Postdoctoral Fellowship Award.

“I’m very grateful to the 20 students who have been part of our research group over these last three years,” Lombardi added. “In August 2017, our laboratory, COAD 123, was an empty room with a wooden crate of unboxed research equipment. Through their hard work and determination, the students transformed that empty space into a functioning biochemistry laboratory. Eleven of the 20 students are graduating seniors this year, and it’s hard for me to imagine the Mount without them. While it will be difficult to see these lab members leave the group, I’m very excited for all the wonderful accomplishments that lie ahead in their futures.”

Additional data has been collected since the grant application submission in February; Lombardi is working with collaborators to prepare a manuscript for publication that will include several Mount undergraduates as coauthors.

About Mount St. Mary’s University

Mount St. Mary’s University is a private, liberal arts, Catholic university in the Catoctin Mountains near historic Emmitsburg, Maryland, with a satellite campus in Frederick, Maryland’s second largest city. The university offers more than 80 majors, minors, concentrations and special programs for traditional undergraduate students, and more than 20 adult undergraduate and graduate level programs as well as 24 NCAA Division I athletic programs. The Mount includes Mount St. Mary’s Seminary, the second oldest in the United States, and the National Shrine Grotto of Our Lady of Lourdes, an idyllic shrine for spiritual reflection located on the hill above the university.

Share article on social media or email:

RoosterBio Signs Cooperative Research and Development Agreement with The Geneva Foundation and the Uniformed Services University


News Image

“Collaborating with Geneva and USU is an important milestone as we have filed patent applications to extend the capabilities of our RTP technology globally,” said Margot Connor, CEO of RoosterBio

RoosterBio, a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems, today announces that it has entered into a Cooperative Research and Development Agreement (CRADA) with The Geneva Foundation (Geneva), a non-profit dedicated to advancing military medicine, and the Uniformed Services University of the Health Sciences (USU), an institution of higher learning within the United States Department of Defense (DoD) on behalf of USU’s 4 Defense Biotechnology, Biomanufacturing, and Bioprinting Center (4D Bio3). Under the terms of the CRADA, RoosterBio will support biofabrication in austere environments and provide subject matter expertise in Ready to Print (RTP) technologies.

“Collaborating with Geneva and USU is an important milestone as we have filed patent applications to extend the capabilities of our RTP technology globally,” said Margot Connor, CEO of RoosterBio. “With this partnership, we aim to show that our cells can support biofabrication in any environment. Our vision is a world where safe and effective regenerative medicines are rapidly developed and are widely available on a global scale, to benefit the lives of patients in need.”

Extensive peer-reviewed medical literature has validated RoosterBio’s novel technology platform for accelerating regenerative medicine. Most relevant to military medicine is RoosterRTP™ human mesenchymal stem/stromal cells (hMSCs) a first-of-its-kind product designed to radically simplify and standardize the most complex and labor-intensive aspects of bioprinting. RTP allows product developers to thaw and use large quantities of hMSCs, avoiding time-, labor-, and cost intensive cell expansion processes allowing for same day bioprinting capabilities, a critical requirement in forward locations that lack resources typically required for cell culture. Geneva has an agreement with USU to support the development and commercialization of scientific and medical technologies and USU seeks to transfer to technology. The collaboration with RoosterBio will encompass multiple projects with the ultimate objectives of saving the lives of deployed service members and translating the results to civilian care.

“Advances in 3D printing and biofabrication have the potential to provide unprecedented benefits for the warfighter, including perhaps the direct repair or replacement of damaged tissues” said Elise Huszar, President and CEO of The Geneva Foundation. “Resulting military benefits include the potential to drastically reduce traditional supply chain and logistical challenges and costs of transporting medical supplies and related items providing both time and cost savings to the U.S. military in resource-limited settings.”

Geneva and USU successfully completed a pilot project involving the biofabrication of medical products and bioprinted tissues in a desert military environment in October 2019 under the federally-funded 4D Bio3 Fabrication in Austere Environments (Fab AE) program. The project supported proof-of-concept demonstrating the feasibility of 3D printing a wide range of personalized health care products in remote geographic locations, notably the 3D print of a meniscus using RoosterBio RTP hMSCs. It was the first demonstration of cyber manufacturing being used whereby complex designs were transmitted to a remote austere location for production. This successful pilot project represented a multi-disciplinary collaboration which included nScrypt and RoosterBio, Inc. nScrypt’s bioprinter, called the Austere BioAssembly Tool (ABAT™), is a lightweight and ruggedized bioprinter that was custom designed by nScrypt based on their 3D printer experiences with the BioFabrication Facility (BFF) on the International Space Station (ISS).

RoosterBio will provide guidance and expertise of future RTP technologies, including an upcoming ISS mission under the 4D Bio3 program. RoosterBio will also provide subject matter expertise to expand 4D Bio3 RTP education and training initiatives for graduate students at USU and cadets at the U.S. Military Academy at West Point in advanced technology areas such as RTP Biofabrication and Tissue Engineering in support of the DoD and 4D Bio3 research mission.

About The Geneva Foundation

The Geneva Foundation is a 501(c)3 non-profit organization that advances military medicine through innovative scientific research, exceptional program management, and a dedication to U.S. service members and veterans, their families, and the global community. Geneva is proud to have over 25 years of experience in delivering full spectrum scientific, technical, and program management expertise in the areas of federal grants, federal contracts, industry sponsored clinical trials, and educational services. http://www.genevaUSA.org

About RoosterBio, Inc

RoosterBio, Inc. is a privately held cell manufacturing platform technology company focused on accelerating the development of a sustainable regenerative medicine industry, one customer at a time. RoosterBio’s products are high-volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio’s innovative products are ushering in a new era of productivity and standardization into the field, accelerating the road to discovery in Regenerative Medicine. http://www.roosterbio.com

Share article on social media or email:

Kite Pharma, Inc. Wins 2020 MEDA Economic Development Project Award


“Frederick County is noted for their bio-medical industries and research, and Kite Pharma is an exceptional addition to their roster.” – Pamela Ruff, Executive Director, MEDA

Kite Pharma is a division of Gilead Sciences based in California. The bio-medical company focuses on developing cancer treatments. Their Maryland manufacturing facility, currently under construction, is located in Urbana, Frederick County.

“Frederick County was excited to welcome Kite Pharma, Inc., a Gilead Company, to our biotechnology community last year. Kite Pharma, Inc. has already become a part of our economic vitality and a leading voice within our region. We nominated Kite Pharma, Inc. for this award and are thrilled the Maryland Economic Development Association saw fit to recognize this project. It’s projects, like the Kite project, that keep Maryland at the forefront of life science in the United States,” says Helen Propheter, Executive Director of Frederick County Economic and Workforce Development.

The facility is projected to be completed in 2020. Kite Pharma has already hired 100 employees for this facility and is expecting to employ 400-700 individuals by the end of 2025.

“Frederick County is noted for their bio-medical industries and research, and Kite Pharma is an exceptional addition to their roster,” says Pamela Ruff, MEDA executive director. “Their land acquisition and ongoing construction are already adding to the local economy, and this development is set to continue with the completion of their facility.”

The MEDA Awards are an annual recognition of Maryland’s best projects, programs and individuals involved in the economic development field. The 2020 awards were presented to the winners on Sept. 22 during the 2020 MEDA Annual Conference.

To learn more, visit http://www.MEDAmd.com.

About Kite Pharma

Kite Pharma, a Gilead Company, is a biopharmaceutical company based in Santa Monica, California. Kite is engaged in the development of innovative cancer immunotherapies. The company is focused on chimeric antigen receptor and T cell receptor engineered cell therapies. For more information on Kite, please visit http://www.kitepharma.com.

About Frederick County Office of Economic Development

The Frederick County Office of Economic Development (OED) is the catalyst for economic growth in Frederick County, with the mission to increase the overall economic health of Frederick County through attracting new businesses in our targeted industries and helping existing businesses be more successful. Please contact OED at info@discoverfrederickmd.com for more information.

About MEDA

MEDA is a nonprofit organization of economic development professionals. Established in 1961, MEDA members promote the economic well-being of Maryland by working to improve the state’s business climate and the professionalism of those in the field of economic development.

MEDA’s membership includes economic development practitioners employed by government, businesses, and chamber of commerce and other professionals with interest in the economy of Maryland. Through its regular meetings, special programs and projects, MEDA members address such diverse issues as local planning, workforce, transportation, international trade, tourism and finance.

MEDA members work diligently transforming lives by creating opportunities, inspiring innovation and enriching communities in Maryland. To learn more about MEDA, visit http://www.medamd.com.

Share article on social media or email:

Lymphoma Research Foundation Launches Multi-Million Dollar Global Initiative to Drive Follicular Lymphoma Clinical Research


This generous gift will allow us to develop and provide the critical tools and resources necessary to meaningfully advance the study of follicular lymphoma and impact patient care.

The Lymphoma Research Foundation (LRF) – the nation’s largest nonprofit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community – today announced the establishment of the Jaime Peykoff Follicular Lymphoma Initiative, named for follicular lymphoma (FL) survivor and wife of Andrew Peykoff II, owner of Niagara Bottling.

Established through the generosity of the Peykoff Family and Niagara Cares, the $10 million Initiative is poised to transform the follicular lymphoma treatment landscape for tens of thousands of patients by harnessing LRF’s unique resources, convening the world’s experts in follicular lymphoma research and patient care, and driving direct investment in clinical research.

“We were so very impressed by the Lymphoma Research Foundation’s extensive background in partnering with world-leading experts to advance the field of lymphomas research as well as the caliber of its Scientific Advisory Board,” said Jaime Peykoff. “We also loved their commitment to investing in early-career scientists to help push forward the pace and openness of lymphoma research. We are very excited to see what will be uncovered and accomplished with this new disease-focus initiative. It’s going to be a great journey!”

”The Lymphoma Research Foundation seeks to eradicate this disease by supporting innovative research and the development of new and improved treatments for lymphoma. Direct investment in cutting-edge science is the primary way we advance our mission,” said Meghan Gutierrez, LRF CEO. “This generous gift will allow us to develop and provide the critical tools and resources necessary to meaningfully advance the study of follicular lymphoma and impact patient care.”

Follicular lymphoma is a slow-growing or indolent form of non-Hodgkin lymphoma (NHL) that accounts for 20 to 30 percent of all NHL cases. While typically an indolent form of lymphoma, FL remains incurable and a continuing challenge for researchers and clinicians. Although most patients respond to the current standard of care, many will require treatment throughout their lifetime; other patients’ inability to achieve a complete remission or those whose disease progresses early results in poorer long-term outcomes.

Through the Jaime Peykoff Follicular Lymphoma Initiative, LRF will mobilize the research community to better understand FL, accelerate therapeutic development and bring innovations and advances to patients who require them faster and more efficiently. The main Initiative components include:

Leadership

LRF assembled a Steering Committee comprised of FL experts to provide thought leadership for the Initiative. This multidisciplinary, multi-institutional panel will ensure all key stakeholders are informed of the Initiative’s goals and identify the most significant areas of unmet needs in clinical FL research.

The Initiative’s Steering Committee includes the following:

  • Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center, Chair
  • Sonali M. Smith, MD, The University of Chicago Medical Center, Vice Chair
  • Stephen Ansell, MD, PhD, Mayo Clinic, Rochester
  • John P. Leonard, MD, Weill Cornell Medicine
  • Brian Link, MD, University of Iowa, Holden Comprehensive Cancer Center
  • Laura Pasqualucci, MD, Columbia University Medical Center
  • John Timmerman, MD, UCLA Jonsson Comprehensive Cancer Center

“We are honored to have assembled such an elite group of experts as part of the Initiative’s leadership,” said Dr. Zelenetz, who also serves as Chair of the LRF Scientific Advisory Board (SAB). “Their extensive background in researching and treating follicular lymphoma and overall dedication to advancing the field in lymphoma research and clinical care makes me confident in and excited for future breakthroughs in this disease.”

International Follicular Lymphoma Scientific Workshop

Building upon more than two decades’ experience as a convener of international scientific consortia and disease-specific research workshops, LRF will develop an international Scientific Workshop to drive collaboration. Follicular lymphoma thought leaders would share early research findings, discuss the results of pivotal clinical trials, and engage in planning exercises designed to advance FL research.

Clinical Research Grants

LRF is committed to funding the most promising lymphoma researchers who have the greatest potential to improve patient care and, ultimately, to improve patient outcomes. Under the expert leadership of the Jaime Peykoff Follicular Lymphoma Initiative Steering Committee and the LRF SAB, LRF will fund both Clinical Investigator Career Development Awards and Senior Investigator Grants to attract senior and early-career investigators and train them in the field of FL research.

“Amidst the continuing COVID-19 pandemic, many scientific research labs across the country were forced to shut down, and funds for research continue to decrease,” said Gutierrez. “We are proud to continue our commitment to the lymphoma community by offering these additional grants within our research portfolio. We thank our supporters, like the Peykoff Family, for making this important work possible.”

For more information about the Jaime Peykoff Follicular Lymphoma Initiative visit lymphoma.org/FLInitiative. To learn more about LRF impact on lymphoma research or additional LRF research programs, visit http://www.lymphoma.org/research.

About the Lymphoma Research Foundation

The Lymphoma Research Foundation (LRF) is the nation’s largest nonprofit organization devoted to funding innovative research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives and patient services. To date, LRF has awarded more than $63 million in lymphoma-specific research.

For additional information on LRF’s research, education and services, visit lymphoma.org.

Share article on social media or email:

EZ Texting Adds Growth-Focused Executive Heather Zynczak to Board of Directors


EZ Texting Adds Heather Zynczak to Board of Directors

EZ Texting, the leader in SMS marketing software for business, today announced the appointment of Heather Zynczak to its Board of Directors. With a career focused on growing companies, Zynczak’s experience and knowledge in building, marketing and selling customer solutions will be vital as EZ Texting scales to meet the current and future needs of its customers.

“As an independent board member, Heather brings to the board a wealth of experience in SaaS marketing and driving strategy with high-growth companies,” said Norman Happ, CEO of EZ Texting. “Her experience includes piloting massive expansions that enabled her last two companies to go public. EZ Texting is fortunate to have her on the board as we grow in an environment with increasing demand for the real-time communications solutions people prefer.”

Zynczak is Chief Marketing Officer of Pluralsight, the world’s leading technology learning platform for enterprises, where she is responsible for all aspects of marketing and digital revenue. During her tenure, the company has grown from just over $100 million to almost $500 million in revenue.

Prior to Pluralsight, she was CMO of Domo, helping build one of the fastest growing tech startups—starting from zero revenue and expanding over four years to approximately $100 million, with up to 100% year-over-year revenue growth. She has held executive positions at Oracle and SAP, led teams at several Silicon Valley startups, and served as a business consultant at Accenture, The Boston Consulting Group and Booz Allen & Hamilton.

“I believe EZ Texting is at an inflection point and primed to be the leader in the market,” said Zynczak. “Customer communication and prospect marketing are vital to any organization. Connecting with your community is especially essential for small and mid-sized business owners—and connecting in the way that they prefer to communicate is paramount. EZ Texting gets that.”

Zynczak finds EZ Texting’s strong leadership team and the innovation and power of the EZ Texting product to be a winning combination. “EZ Texting is in the next phase of its growth, and I look forward to providing guidance as the business moves forward.”

About EZ Texting

EZ Texting is a SaaS company that delivers the fastest, easiest and most reliable way to connect. It has served over 160,000 customers and is the #1 SMS platform for business users, setting the standard for business texting. Our messaging solutions allow businesses to quickly and effectively reach and engage their mobile audiences. With employees around the world, EZ Texting is continuously recognized as a Best Place to Work, as well as a top product for small and mid-market businesses. The company is backed by Morgan Stanley Expansion Capital, Investor AB and ROCA Partners. To find out more, follow us on Twitter and LinkedIn.

Share article on social media or email:

Making Next-Gen into “Now Gen,” Upcoming Webinar Hosted by Xtalks


Xtalks Logo

Xtalks Life Science Webinars

So what are the barriers preventing or delaying adoption?

Automation, and its big brother AI, have been hot topics in Pharmacovigilance for several years now, linked to the technology’s promise to transform all kinds of high-volume manual processes. So why isn’t there universal adoption within the industry?

In the experience of this webinar’s presenter Dr. John Price, a consultant to life sciences organizations around the world, there has been remarkably sparse uptake of next-generation tech solutions for case intake, given their scope for process transformation.

So what are the barriers preventing or delaying adoption? As an advisory Board member to consulting services provider Arriello – which promotes and uses an automated case-intake solution to expedite and enhance the quality and completeness of adverse event reporting – Dr. Price has a rounded interest in discovering more about what is going on. This curiosity prompted a US/UK survey of 200 PV professionals, commissioned by Arriello and conducted in June 2020, investigating attitudes towards case intake automation and adjacent PV activities.

Join Dr. John Price, MB ChB, PhD, BSc, Pharmacovigilance Consultant, Arriello Advisory Board member in a live webinar on Thursday, October 15, 2020 at 11am EDT (4pm BST/UK).

For more information or to register for this event, visit Case Intake: Making Next-Gen into “Now Gen.”

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Omixon launches OmniType, multiplex for NGS-based HLA genotyping


OmniType

Omixon has created a well thought-out, fast and extremely streamlined process to perform HLA NGS testing. They have a great team that supports every aspect of their product and workflow and seek to make us successful

Global molecular diagnostics company, Omixon, headquartered in Budapest with US offices in Cambridge, MA, announce the launch of OmniType, a 11-locus multiplex human leukocyte antigen (HLA) genotyping assay and software product for use on the Illumina® sequencing platforms (such as MiSeq, MiniSeq and iSeq). OmniType offers a revolutionary single working-day workflow that allows processing of samples from gDNA to a ready-to-sequence library in about 6 hours and achieving final results that can be reported early the next day.

“Our goal is to constantly listen not only to our customers’ needs, but also to the entire HLA community, and to deliver products that fulfill those needs and beyond. I strongly believe that OmniType will prove this commitment” said Libor Kolesar, Senior Field Applications Scientist & Assay Product Manager. Omixon successfully completed its Early Access Program (EAP) that gave fifteen (15) HLA laboratories worldwide the opportunity to test OmniType and provide valuable feedback. The initial results confirmed the expected high quality and accuracy of HLA genotypes, while the overall feedback from HLA lab technologists regarding the OmniType protocol was outstanding. Specifically, users enjoyed the protocol simplicity, as well as the streamlined and fast workflow. The OmniType protocol can be performed in about 6 hours (from gDNA normalization to ready-to-sequence library) allowing the users to comfortably fit it in a single work shift. While liquid handling automation becomes optional, both pre- and post-PCR steps in the OmniType protocol can be readily automated. The OmniType product includes the widely used HLA Twin software that uses 2 independent algorithms, including a de novo assembly approach, resulting in fast analysis and a streamlined, user-friendly data review workflow, with minimal hands-on time.

OmniType can out-perform the current Next Generation Sequencing (NGS)-based HLA typing tests on most relevant metrics in clinical labs including turnaround time, simplicity, reliability and accuracy. These metrics have been found to be particularly important for laboratories testing solid organ pre-transplant patients (SOT) where short turnaround time and ease of use are critical for implementation of the NGS technology. NGS is a pivotal technology for SOT patients that allows for novel transplant matching methods such as epitope/eplet-based methods opening up the pool of acceptable organs for transplantation. Recent information shows that a substantial number of SOT labs still do not use NGS due to its long turnaround time and protocol complexity. The simple and fast workflow of OmniType offers these labs the opportunity to successfully adopt NGS, thus providing the possibility for these labs to contribute to better transplantation outcomes.

“Omixon has created a well thought-out, fast and extremely streamlined process to perform HLA NGS testing. They have a great team that supports every aspect of their product and workflow and seek to make us successful” said John May, Chief Medical Technologist, Immuno-Molecular Pathology Lab at University of Kentucky.

With over 7 years of experience as a leading provider of NGS-based products for HLA typing, Omixon has developed a wide network of logistics, including 4 warehouses and 3 manufacturing facilities in both Europe and the Americas to better serve all laboratories worldwide and to overcome any potential challenges related to the COVID pandemic and beyond. Additionally, Omixon has been known for the very high standard of customer support via its remote Technical Support team and its highly skilled Field Applications Scientist team.

Omixon has an innovative molecular diagnostics pipeline; more announcements are expected to come on new product launches and future EAPs.

Contacts at Omixon

Attila Berces, PhD

Chief Executive Officer

attila.berces@omixon.com

+36 70 574 8001

Nora Nagy, MBA

Head of Market Development and Marketing

nora.nagy@omixon.com

+36 30 633 3050

About Omixon

Omixon is a global molecular diagnostics company, headquartered in Budapest, Hungary, with US offices in Cambridge, MA that commercializes disruptive technologies for clinical and research laboratories. Omixon’s Holotype HLA is the world’s leading NGS-based HLA genotyping product that delivers the most accurate high-resolution HLA genotyping available, and is used in more than 50 hospitals worldwide. Omixon’s research software, HLA Explore analyzes data from any sequencing technology and determines HLA genotypes from Whole Exome/Genome Sequencing experiments. Omixon maintains an active grant-funded research program with a product pipeline focused on pre- and post-transplantation, and HLA genotyping applications beyond transplantation. For more information, visit http://www.omixon.com

Share article on social media or email:

Surprise Medical Bills are in the Headlines Again, Here’s How We Solve the Problem – Industry Analysis by Loyale Healthcare


Consumers, regulators, Congress and the administration are determined to fix surprise medical bills.

A patient-centered approach is the only sustainable way for healthcare to solve the surprise medical bills problem, resist intensifying competition and respond to an increasingly discerning healthcare consumer. – Kevin Fleming, CEO, Loyale Healthcare

Late last week, the president issued two executive orders affecting the U.S. Healthcare industry as reported in an article published Sept. 24 by AJMC. The first declares the establishment of a national policy to protect patients with preexisting conditions, regardless of the fate of the Affordable Care Act (ACA), which faces another Supreme Court challenge later this year.

The second executive order addresses surprise medical billing. It directs the Secretary of the Department of Health and Human Services, Alex Azar, to work with Congress to get legislation passed on surprise medical billing by Jan. 1, 2021. If Congress is unable to pass legislation by that date, the Secretary is instructed to “investigate executive actions and regulatory actions.”

Apart from questions about policy details and enforceability, the timing of the orders underscores just how big these issues are in the eyes of Americans, especially American voters. Even as the industry continues its struggle with COVID-19 fallout, the pressure to ensure coverage and improve patient affordability has not eased. If anything, it’s intensifying.

These are not new issues, as anyone paying attention to the industry would readily acknowledge. But these executive orders suggest they have become more important than ever. With tens of millions losing employer-sponsored coverage as a result of COVID-19 job losses and millions more experiencing financial distress due to un- or under-employment, the pressure on industry stakeholders to provide adequate access to coverage and reduce unmanageable medical bills has been unrelenting.

With respect to surprise medical bills, some insightful analysis offered by Sally C. Pipes, President, CEO and Thomas W. Smith Fellow in Health Care Policy at the Pacific Research Institute, may offer a better path toward curing this chronic industry problem. In “Surprise! There’s a better fix for surprise bills,” Ms. Pipes offers an alternative to the “two competing approaches that have been languishing in Congress;” one favoring insurers the other favoring healthcare providers.

She goes on to assert that, “Congress should instead implement a solution that privileges the interests of patients. Such a fix would give people accurate pricing and coverage information before they receive care – and hold insurers and providers accountable if that information is inaccurate.” Instead of excluding the patient from the process, pre-treatment price transparency would serve to, “prevent the most egregious episodes of surprise billing – without yielding the negative consequences of arbitration or benchmarking,” the competing approaches benefiting providers and insurers.

We at Loyale Healthcare agree. Any solution to surprise bills must place patients at the center, where the pain of these bills is felt most keenly. In an article published earlier this summer titled, “COVID-19 and the Growing Demand for Healthcare Transparency,” we acknowledged the industry’s longstanding inability to inform consumers (patients) with critical pricing information. The technology-enabled solution we proposed was composed of six fundamental operational principles to empower patients throughout their care journey:

1.    The presentation of upfront cost estimates for a patient’s anticipated course of treatment and all associated expenses, including pre-service eligibility so a reliable out-of-pocket estimate can also be presented.

2.    The availability of multiple payment options to address patient affordability, along with provider-configured options for a variety of payment plans and incentives.

3.    Interactive self-service options with secure, highly personalized online experiences that resemble the best online interactions in other sectors.

4.    The delivery of consolidated, plain-language healthcare bills that combine and simplify the many bills that often accompany an episode of care, so bills are easy to understand and just as easy to pay.

5.    Personalized, contextual digital communications that honor each patient’s preferences and behavior – from beginning to end throughout the patient’s care journey until their financial obligation is fulfilled.

6.    End-to-end provider analytics so hospitals and health systems have the information they need to make evidence-based decisions about their patient-payment portfolios, as care-givers and operators.

This approach, powered by technology platforms like Loyale’s Patient Financial Manager™ enlists both payers and providers, supporting mutually sustainable policies that assure patient access to care without the dread of receiving a financially devastating bill.

The Longer-Term Impacts of Patient Transparency on Provider Growth

The benefits of providing patients with reliable information about eligibility and price go well beyond solving the surprise medical bill problem. In a marketplace where the purchasing power has shifted to patients, transparency becomes a competitive necessity for providers interested in preserving or growing their share of the care delivery market. And it’s safe to say the competition has never been tougher.

Companies like CVS Health/Aetna, Walgreens and Walmart Health have recently announced aggressive growth plans. Virtual care has been enthusiastically embraced by consumers. With the possibility of permanent regulatory change allowing physician access across state borders virtual care could open markets to higher-value providers anywhere. If the goal of regulation is to encourage competition and put downward pressure on consumer costs, it would appear that healthcare’s patient-centered transformation will be more sudden and more profound than anyone might have imagined just a few short months ago.

Tackling Surprise Billing Calls for Much More than Mere Compliance

In our experiences working with large, multi-facility healthcare networks across the U.S., we had observed shifts in the healthcare consumer marketplace before COVID-19. These shifts have become even more pronounced since pandemic began. As patients’ willingness to engage with their providers in a virtual setting has grown, so too have patients’ expectations for other forms of patient engagement.

We and our clients have learned that, when given the option, many patients will use their “digital front door” to access price information and set up their own payment plans without any human intervention. Perhaps more important, collecting on these self-selected plans outperforms other collection methods, at a fraction of the cost. Armed with reliable price information and empowered with the ability to get the care they need without breaking their budgets, patients seek care with confidence. At the same time, providers improve their patients’ experiences, encourage patient loyalty and drive better financial performance.

Last year, we published an article titled, “Medicare’s Price Transparency Rules Alone Don’t Deliver What Patients Need – A Patient First Approach Does.” In it, we noted that “the new CMS rules threaten to distract providers and payers from the larger, more important issue facing healthcare and patients.” We believe, and our clients’ experiences confirm, that a patient-centered approach to price transparency is the only sustainable way for healthcare to solve the surprise medical bills problem, resist intensifying competitive pressures and respond to an increasingly discerning healthcare consumer.

Kevin Fleming is the CEO of Loyale Healthcare

About Loyale

Loyale Patient Financial Manager™ is a comprehensive patient financial engagement technology platform leveraging a suite of configurable solution components including predictive analytics, intelligent workflows, multiple patient financing vehicles, communications, payments, digital front doors and other key capabilities.

Loyale Healthcare is committed to a mission of turning patient responsibility into lasting loyalty for its healthcare provider customers. Based in Lafayette, California, Loyale and its leadership team bring 27 years of expertise delivering leading financial engagement solutions for complex business environments. Loyale currently serves approximately 12,000 healthcare providers across 48 states. Loyale is proud to have an enterprise-level strategic partnership with Parallon which includes the deployment of Loyale’s industry leading technology at all HCA hospitals and Physician Groups.

MI Windows and Milgard Raise Awareness and Funds for Breast Cancer Research


“MI, Milgard, and our Charitable Foundation are determined to help in the fight against this awful disease by raising awareness and contributing resources to those searching for a cure,” said MI CEO Matt DeSoto.

MI Windows and Milgard Windows & Doors will donate more than $50,000 towards breast cancer research in October. The companies’ non-profit affiliate, the MI Charitable Foundation is committed to donating $25,000 to both the National Breast Cancer Foundation and the Breast Cancer Research Foundation.

In addition, both MI and Milgard are showing support for breast cancer awareness in the following ways:

Pink Labels: The addition of a pink-colored National Fenestration Rating Council (NFRC) label will be placed on each window and patio door produced in the month of October. These labels help homeowners compare energy efficiency on windows and doors.

Local Outreach: Each MI and Milgard facility is raising funds through sales of pink-branded merchandise for a local breast cancer charity in their area.

Spread Awareness on Social Media: The MI Charitable Foundation will donate $10 for every Facebook, Instagram, or Twitter post that includes the hashtag #MIGoPink or #MilgardGoPink up to $10,000, which will be split between the National Breast Cancer Foundation and the Breast Cancer Research Foundation.

“MI, Milgard, and our Charitable Foundation are determined to help in the fight against this awful disease by raising awareness and contributing resources to those searching for a cure,” said MI CEO Matt DeSoto. “Giving back is ingrained in our culture. By using pink labels and donating to these worthy foundations, we hope to inspire others to join the fight against breast cancer.”

MI and Milgard encourage those who wish to participate and donate to visit: http://www.miwindows.com/2020GoPink.

About the MI Charitable Foundation

In 2015, the MI Charitable Foundation was founded on the belief that we all have an obligation to help our fellow citizens. The charitable foundation has committees at each of its locations that raise and donate funds for local initiatives as well as three noteworthy causes – veteran’s affairs, child wellbeing, and cancer.

About MI

MI is a fenestration products manufacturer that owns and operates two brands – MI Windows and Doors and Milgard Windows & Doors. MI is one of the nation’s largest suppliers of precision-built and energy-efficient windows and doors. With more than 10 manufacturing plants located throughout the United States, MI brands manufacture stylish, high-performance, and market-preferred products for both new construction and replacement applications. For more information, visit http://www.miwindows.com or http://www.milgard.com.

###

Share article on social media or email: